# TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT

> **NCT03529149** · PHASE4 · UNKNOWN · sponsor: **Xuanwu Hospital, Beijing** · enrollment: 90 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **COMBINATION_PRODUCT:** Urapidil Hydrochloride Injection

## Key facts

- **NCT ID:** NCT03529149
- **Lead sponsor:** Xuanwu Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-08
- **Primary completion:** 2019-06-01
- **Final completion:** 2019-06-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2018-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03529149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03529149, "TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03529149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*